Regenerative Therapy

Regenerative Therapy

Volume 21, December 2022, Pages 442-452
Regenerative Therapy

Original Article
CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy

https://doi.org/10.1016/j.reth.2022.09.009Get rights and content
Under a Creative Commons license
open access

Highlights

  • The CRISPR/Cas9 system with AAV1/2 could knock in/out efficiently in UC-MSCs.

  • B2M-HLA-G fusion gene was successfully introduced and expressed to the cell surface.

  • Gene edited UC-MSCs were capable of evading allogeneic immune responses.

Abstract

Introduction

Mesenchymal stromal cells (MSCs) hold the potential for application as cellular therapy products; however, there are many problems that need to be addressed before the use in clinical settings, these include the heterogeneity of MSCs, scalability in MSC production, timing and techniques for MSC administration, and engraftment efficiency and persistency of administered MSCs. In this study, problems regarding immune rejection caused by human leukocyte antigen (HLA) mismatches were addressed.

Methods

Umbilical cord-derived MSCs (UC-MSCs) were gene-edited to avoid allogeneic immunity. The HLA class I expression was abrogated by the knock-out of the beta-2-microglobulin (B2M) gene; instead, the B2M-HLA-G fusion gene was knocked-in using the CRISPR/Cas9 system in combination with adeno-associated virus (AAV).

Results

Cell surface markers on gene-edited UC-MSCs were not different from those on primary UC-MSCs. The gene-edited UC-MSCs also retained the potential to differentiate into adipocytes, osteoblasts, and chondrocytes. B2M gene knock-out alone protected cells from allogeneic T cell immune responses but were vulnerable to NK cells. B2M gene knock-out in combination with B2M-HLA-G knock-in protected cells from both T cells and NK cells. The B2M-HLA-G knock-in MSCs retained a good immunosuppressive ability and the addition of these cells into the mixing lymphocyte reaction showed a significant inhibition of T cell proliferation.

Conclusions

The results of this study demonstrated the possibility that the CRISPR/Cas9 system combined with AAV can be used to effectively disrupt/introduce any gene into UC-MSCs. Our findings suggest that the gene-edited cell line produced here using this method may have a higher ability to escape the cytotoxic activity of immune cells than primary cells, thereby being more advantageous for long-term graft survival.

Keywords

UC-MSCs
AAV
CRISPR/Cas9
HLA-G
Allogenic rejection

Abbreviations

AAV
adeno-associated virus
FASL
FAS ligand
GVHD
graft versus host disease
HLA
human leukocyte antigen
HR
homologous recombination
HSC
hematopoietic stem cells
ITR
inverted terminal repeats
KIR
killer-cell immunoglobulin-like receptors
LILR
leukocyte immunoglobulin-like receptors
MLR
mixed lymphocyte reaction
MSC
mesenchymal stromal cells
PBMC
peripheral blood mononuclear cells
PS
penicillin–streptomycin
SD
standard deviation

Cited by (0)

Peer review under responsibility of the Japanese Society for Regenerative Medicine.

1

These two authors contributed equally to this work.